Adagia Partners GmbH

What they fund

• Mid-Market Buyouts: Controlling stakes in companies with €150m to €600m enterprise value [1].
• Healthcare & MedTech: Companies like Schwind eye-tech-solutions, focusing on medical devices and services [2].
• Business Services & Tech: Sectors offering defensive traits or high growth, targeted for operational value creation [1].

Credibility: The firm's website specifies the enterprise value range and sector focus [1].

Investment thesis

Adagia Partners targets controlling stakes in European mid-market companies with an enterprise value of €150m to €600m, leveraging operational influence without the complexity of large-cap transactions [1]. The firm concentrates capital in Healthcare, Business Services, and Tech, sectors chosen for their defensive characteristics or high-growth potential [1]. A core strategic motion is a buy-and-build strategy, aiming to consolidate fragmented markets through platform acquisitions and add-on roll-ups [1]. The firm operates as a responsible investor, emphasizing environmental respect, social responsibility, and ethical governance as part of its value creation framework [1].

Credibility: The firm's own website details the €150m-€600m EV range, sector focus, and responsible investment commitments [1].

Value add

Adagia Partners provides operational support through a team with over 100 years of combined experience, focusing on strategic guidance and governance [1]. The firm emphasizes responsible investing, integrating ESG factors into its investment process and portfolio management [1].

Fit verdict: Suitable for founders seeking a long-term partner with operational expertise in healthcare and business services, particularly those open to consolidation.

Founder diligence script:

• How does Adagia structure its buy-and-build strategy for add-on acquisitions?
• What specific operational resources does the firm deploy to support portfolio companies?
• How are ESG commitments integrated into the firm's value creation plan?

Credibility: The firm's website highlights its team's experience and responsible investment commitments [1].

Portfolio focus

• Schwind eye-tech-solutions: A German medical technology company providing ophthalmic lasers, acquired by Adagia in 2022 [2].

Credibility: Wikipedia details Adagia's acquisition of Schwind, a key portfolio company in the healthcare/tech sector [2].

Notable investments & exits

• Portfolio Count — The firm currently has 1 active investment in its portfolio, indicating a relatively new or highly concentrated investment track record as of the last update [Profile].
• Specific Investments — No specific portfolio company names or exit details are available in the provided research sources [Profile].

Strategic implications

Adagia's focus on mid-market buyouts in healthcare and business services positions it to capitalize on consolidation trends in fragmented European markets. The firm's responsible investment approach may attract ESG-focused limited partners and portfolio companies. The €1.3bn platform size suggests significant deployment capacity, but the firm's ability to source and execute deals at scale will be critical to its success.

Where they could go further

Adagia could enhance its value proposition by developing a more robust operational support framework for portfolio companies. The firm could expand its geographic focus beyond France and Germany to access a larger pool of mid-market opportunities. Adagia could improve its transparency by disclosing more details about its investment process and performance metrics.